Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease

Brain

Volumn 130, Issue 1, 2007, Pages 143-150

  Ries, M ^a   Kim, H J ^b   Zalewski, C K ^b   Mastroianni, M A ^a   Moore, D F ^c   Brady, R O ^a   Dambrosia, J M ^a   Schiffmann, R ^a   Brewer, C C ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Fabry disease; Hearing impairment; Peripheral neuropathy; Stroke; X linked disorder

Indexed keywords

ALPHA GALACTOSIDASE;

ACOUSTIC REFLEX; ADOLESCENT; ADULT; AGED; ARTICLE; AUDIOLOGY; AUDITORY THRESHOLD; BLOOD VESSEL INJURY; CEREBROVASCULAR DISEASE; CHILD; COCHLEA; COLD; ENZYME ACTIVITY; FABRY DISEASE; FEMALE; HEARING LOSS; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NEUROPATHY; PERCEPTION DISORDER; PERIPHERAL NEUROPATHY; PREVALENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; UREA NITROGEN BLOOD LEVEL; WHITE MATTER; WORD RECOGNITION;

ADOLESCENT; ADULT; AGED; ALPHA-GALACTOSIDASE; CHILD; CROSS-SECTIONAL STUDIES; EAR, MIDDLE; FABRY DISEASE; FEMALE; HEARING LOSS; HUMANS; LANGUAGE; MALE; MICROCIRCULATION; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; PSYCHOLOGICAL TESTS; RETROSPECTIVE STUDIES; SENSORY THRESHOLDS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TELENCEPHALON; TINNITUS;

EID: 33845884323     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awl310     Document Type: Article

References (33)

1. Altarescu G, Moore DF, Pursley R, Campia U, Goldstein S, Bryant M, et al. Enhanced endothelium-dependent vasodilation in Fabry disease. Stroke 2001a; 32: 1559-62.
2. Altarescu GM, Goldfarb LG, Park KY, Kaneski C, Jeffries N, Litvak S, et al. Identification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease. Clin Genet 2001b; 60: 46-51.
3. ANSI S-. American national standard specification for audiometers. New York, NY: American National Standards Institute; 1989.
4. ANSI S-. American national standard maximum permissible ambient noise levels for audiometric test rooms. New York, NY: American National Standards Institute; 1991.
5. Bird TD, Lagunoff D. Neurological manifestations of Fabry disease in female carriers. Ann Neurol 1978; 4: 537-40.
6. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967; 276: 1163-7.
7. Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002; 81: 122-38.
8. DeGraba T, Azhar S, Dignat-George F, Brown E, Boutiere B, Altarescu G, et al. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 2000; 47: 229-33.
9. Dubno JR, Lee FS, Klein AJ, Matthews LJ, Lam CF. Confidence limits for maximum word-recognition scores. J Speech Hear Res 1995; 38: 490-502.
10. Dyck PJ, O'Brien PC. Quantitative sensation testing in epidemiological and therapeutic studies of peripheral neuropathy. Muscle Nerve 1999; 22: 659-62.
11. Gadoth N, Sandbank U. Involvement of dorsal root ganglia in Fabry's disease. J Med Genet 1983; 20: 309-12.
12. Germain DP, Avan P, Chassaing A, Bonfils P. Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Med Genet 2002; 3: 10.
13. Hajioff D, Enever Y, Quiney R, Zuckerman J, Mackermot K, Mehta A. Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy. J Inherit Metab Dis 2003; 26: 787-94.
14. International Organization for Standardization. Acoustics - threshold of hearing by air conduction as a function of age and sex for otologically normal persons. Geneva: ISO; 1984.
15. Klug H, Zabel R, Evers U. [Fabry disease: clinical, biochemical and electron microscopical studies (author's translation)]. Dermatol Monatsschr 1979; 165: 46-54.
16. Kusiak JW, Quirk JM, Brady RO. Purification and properties of the two major isozymes of alpha-galactosidase from human placenta. J Biol Chem 1978; 253: 184-90.
17. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001a; 38: 769-75.
18. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations, impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001b; 38: 750-60.
19. Margolis RH, Heller JW. Screening tympanometry: criteria for medical referral. Audiology 1987; 26: 197-208.
20. Mazzoli M, van Camp G, Newton V, Giarbini N, Declau F, Parving A. Recommendations for the description of genetic and audiological data for families with nonsyndromic hereditary hearing impairment. Audiol Med 2003; 1: 148-50.
21. Morrell CH, Gordon-Salant S, Pearson JD, Brant LJ, Fozard JL. Age- and gender-specific reference ranges for hearing level and longitudinal changes in hearing level. J Acoust Soc Am 1996; 100: 1949-67.
22. Moore DF, Altarescu G, Ling GS, Jeffries N, Frei KP, Weibel T, et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002; 33: 525-31.
23. Moore DF, Altarescu G, Barker WC, Patronas NJ, Herscovitch P, Schiffmann R. White matter lesions in Fabry disease occur in 'prior' selectively hypometabolic and hyperperfused brain regions. Brain Res Bull 2003; 62: 231-40.
24. O'Brien BD, Shnitka TK, McDougall R, Walker K, Costopoulos L, Lentle B, et al. Pathophysiologic and ultrastructural basis for intestinal symptoms in Fabry's disease. Gastroenterology 1982; 82: 957-62.
25. Ries M, Ramaswami U, Parini R, Lindblad B, Whybra C, Willers I, et al. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr 2003; 162: 767-72.
26. Ries M, Gupta S, Moore DF, Sachdev V, Quirk JM, Murray GJ, et al. Pediatric Fabry disease. Pediatrics 2005; 115: e344-55.
27. Ries M, Clarke JTR, Whybra C, Timmons M, Robinson C, Schlaggar BL, et al. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 2006; 118: 924-32.
28. Schachern PA, Shea DA, Paparella MM, Yoon TH. Otologic histopathology of Fabry's disease. Ann Otol Rhinol Laryngol 1989; 98: 359-63.
29. Schiffmann R, Floeter MK, Dambrosia JM, Gupta S, Moore DF, Sharabi Y, et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 2003; 28: 703-10.
30. Sessa A, Toson A, Nebuloni M, Pallotti F, Giordano F, Battini G, et al. Renal ultrastructural findings in Anderson-Fabry disease. J Nephrol 2002; 15: 109-12.
31. Silman S, Gelfand SA. The relationship between magnitude of hearing lossandacousticreflexthresholdlevels. J Speech Hear Disord 1981; 46: 312-6.
32. Sindhusake D, Mitchell P, Newall P, Golding M, Rochtchina E, Rubin G. Prevalence and characteristics of tinnitus in older adults: the Blue Mountains Hearing Study. Int J Audiol 2003; 42: 289-94.
33. Slattery WH, Fisher LM, Iqbal Z, Liu N. Oral steroid regimens for idiopathic sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2005; 132: 5-10.